[ad_1]
Analysts are betting on expected launches in the US and Europe, lower price erosion in the US, R&D investments in biosimilars, and Aurobindo Pharma Ltd.’s global injectables business after the third-quarter earnings.Aurobindo Pharma’s net profit fell 19% year-on-year, missing estimates. Its revenue was up 7% at Rs 6,407 crore, and Ebidta margins were at 14.9%.
[ad_2]
Source link
